Lexaria’s DehydraTECH Technology Improves Performance of GLP-1 drug, Rybelsus®

Lexaria Bioscience (Nasdaq: LEXX) has demonstrated that its DehydraTECH technology improves the performance of GLP-1 drug, semaglutide, in a human pilot study. DehydraTECH-powered semaglutide achieved sustained higher levels of semaglutide in subjects’ blood, faster achievement of peak drug delivery and reduced side effects. The company’s share price rose 25% in morning trading following the news.

Final results from the study are expected to be released in late Q4 2023 or early Q1 2024.


Lexaria’s study is being conducted by a prominent university research center and is comparing a single 7 mg oral dose of Rybelsus to a matching dose of Rybelsus that has been formulated using DehydraTECH processing technology.

Seven healthy subjects were dosed, four of whom received DehydraTECH GLP-1, and three of whom received the control. The seven subjects are expected to return to the study site in December to be dosed a second time in the reverse order following the study’s  “cross-over” design.

24 hours after dose administration, the DehydraTECH GLP-1 group’s blood semaglutide levels were still approximately 25% higher than the control levels.

Lexaria has previously demonstrated that DehydraTECH can greatly improve the pharmacokinetic performance of many orally administered drugs into the bloodstream.

Rybelsus (semaglutide) is the only oral GLP-1 drug approved by the FDA to treat diabetes and manage weight loss.

DehydraTECH is a patented drug delivery formulation and processing platform technology designed to improve the way active molecules enter the bloodstream upon oral ingestion.

About Lexaria Bioscience

Lexaria Bioscience’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lexaria’s DehydraTECH Technology Improves Performance of GLP-1 drug, Rybelsus®

Catie Corcoran

Biotech Editor